drugset / Trial / NCT00562887

Dose Ranging Study Comparing the Efficacy, Safety and Pharmacokinetics of Intravenous Infusions of ABT-874 vs Placebo in Subjects With Active Crohn's Disease

NCT00562887

Phase 2 Terminated 246 enrolled Abbott
RandomizedParallel-groupTriple-blindTreatment

Summary

To compare the efficacy, safety and pharmacokinetics of ABT-874 to placebo in subjects who have moderately to severely active Crohn's Disease.

Timeline

Start
2007-11
Primary completion
2010-04
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject briakinumab Monoclonal antibody 400 mg Intravenous
Subject briakinumab Monoclonal antibody 700 mg Intravenous

Indications